Amstutz A, Schandelmaier S, Ewald H, Speich B, Schwenke JM, Schönenberger CM, Schobinger S, Agoritsas T, Tomashek KM, Nayak S, Makowski M, Morales-Ortega A, Bernal-Bello D, Pomponio G, Ferrarini A, Ghazaeian M, Hall F, Bond S, García-Morales MT, Jiménez-González M, Arribas JR, Guimaraães PO, Tavares CAM, Berwanger O, Yazdanpanah Y et al. (2025)
Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials
Lancet Respir Med, 13 (6), 530-544
DOI 10.1016/S2213-2600(25)00055-4, PubMed 40378861

Andersen T, Ueland T, Ghukasyan Lakic T, Åkerblom A, Bertilsson M, Aukrust P, Michelsen AE, James SK, Becker RC, Storey RF, Wallentin L, Siegbahn A, Kontny F, PLATO Investigators (2025)
Correction to: C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes
Arterioscler Thromb Vasc Biol, 45 (7), e336
DOI 10.1161/ATV.0000000000000187, PubMed 40560990

Augustin M, Bewley A, Brüggen MC, de Bruin-Weller MS, Ezzedine K, Ferrucci SM, Gkalpakiotis S, Herranz P, Johansson EK, Kampe T, Lapeere H, Legat FJ, Rehbinder EM, Szepietowski JC, Torres T, Vestergaard C, Werfel T, Domenech A, Massana E, Koscielny V, Narayanan S, Kasujee I, Gutermuth J (2025)
European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol
BMJ Open, 15 (7), e102155
DOI 10.1136/bmjopen-2025-102155, PubMed 40645621